Utama › Osteosarkoma › Alabama
Kajian klinikal Osteosarkoma di Alabama
7 kajian untuk Osteosarkoma sedang mencari peserta di lokasi di Alabama.
Bandar di Alabama
Teks kajian rasmi (Bahasa Inggeris)
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- University of Alabama/Children's of Alabama, Birmingham
Mengambil pesertaFasa 1/2
Sehingga umur 26 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- University of Alabama/Children's of Alabama, Birmingham
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06541262Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Children's Hospital of Alabama, Birmingham
Mengambil pesertaFasa 3
Sehingga umur 50 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05235165Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital of Alabama, Birmingham
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT05297734A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital of Alabama/UAB, Birmingham
Mengambil pesertaFasa 2
18 Months – 40 Years · Semua jantina · Dikemas kini 12 Ogo 2025 · NCT05135975Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.